Moderna provides business and pipeline updates at 42nd annual j.p. morgan healthcare conference

Company announces product sales for 2023 of approximately $6.7 billion (unaudited); u.s. covid-19 market share season to date increased to 48% in 2023, up from 37% in 2022 company reiterates 2024 expected product sales of approximately $4 billion, planned return to sales growth in 2025 and expectation to break even in 2026 through product launches and disciplined investment company highlights nine late-stage programs with anticipated milestones in 2024 and 2025 cambridge, ma / accesswire / january 8, 2024 / moderna, inc. (nasdaq:mrna) today announced business updates and progress on the company's pipeline of transformative mrna medicines. moderna enters 2024 with 45 therapeutic and vaccine programs, nine of which are in late-stage development.
MRNA Ratings Summary
MRNA Quant Ranking